In last trading session, Adc Therapeutics SA (NYSE:ADCT) saw 1.14 million shares changing hands with its beta currently measuring 1.57. Company’s recent per share price level of $2.12 trading at $0.21 or 10.99% at ring of the bell on the day assigns it a market valuation of $204.99M. That closing price of ADCT’s stock is at a discount of -184.91% from its 52-week high price of $6.04 and is indicating a premium of 44.34% from its 52-week low price of $1.18. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.8 million shares which gives us an average trading volume of 779.93K if we extend that period to 3-months.
For Adc Therapeutics SA (ADCT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adc Therapeutics SA (NYSE:ADCT) trade information
Upright in the green during last session for gaining 10.99%, in the last five days ADCT remained trading in the green while hitting it’s week-highest on Wednesday, 12/18/24 when the stock touched $2.12 price level, adding 4.07% to its value on the day. Adc Therapeutics SA’s shares saw a change of 27.71% in year-to-date performance and have moved 7.07% in past 5-day. Adc Therapeutics SA (NYSE:ADCT) showed a performance of 2.91% in past 30-days. Number of shares sold short was 3.01 million shares which calculate 6.98 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 73.5% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 13. It follows that stock’s current price would drop -230.19% in reaching the projected high whereas dropping to the targeted low would mean a loss of -230.19% for stock’s current value.
Adc Therapeutics SA (ADCT) estimates and forecasts
Statistics highlight that Adc Therapeutics SA is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -20.00% of value to its shares in past 6 months, showing an annual growth rate of 42.52% while that of industry is 17.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -10.46% during past 5 years.
Adc Therapeutics SA (NYSE:ADCT)’s Major holders
Insiders are in possession of 20.64% of company’s total shares while institution are holding 63.22 percent of that, with stock having share float percentage of 79.67%. Investors also watch the number of corporate investors in a company very closely, which is 63.22% institutions for Adc Therapeutics SA that are currently holding shares of the company. REDMILE GROUP, LLC is the top institutional holder at ADCT for having 15.27 million shares of worth $48.25 million. And as of 2024-06-30, it was holding 18.4964 of the company’s outstanding shares.
The second largest institutional holder is PROSIGHT MANAGEMENT, LP, which was holding about 9.57 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.5926 of outstanding shares, having a total worth of $30.24 million.
